Cipla, one of India’s leading pharmaceutical companies, is preparing to foray into the growing weight management segment in the country, Managing Director and Global CEO Umang Vohra announced in the company’s Annual Report for 2024–25.
“Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche indications,” Vohra told shareholders. “Obesity is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions.”
Cipla’s move comes as several domestic and global pharma players intensify their focus on obesity and diabetes care. Global giants such as Eli Lilly and Novo Nordisk have already introduced advanced anti-obesity treatments in India — Mounjaro and Wegovy, respectively — expanding access to novel weight loss therapies aimed at both chronic weight management and cardiovascular risk reduction.
Cipla is also strengthening its footprint in the central nervous system (CNS) therapeutic area. As part of this strategy, the company has successfully in-licensed Sanofi’s India CNS portfolio, which includes Frisium, a leading anti-epileptic brand.
“Building on this momentum, we aim to pursue similar in-licensing agreements or acquisitions in niche indications such as attention deficit hyperactivity disorder (ADHD) and Parkinson’s disease,” Vohra added.
Cipla continues to address global health priorities, including antimicrobial resistance (AMR). Vohra shared that the company’s AMR portfolio is shifting from volume-driven offerings to innovation-led solutions, with four novel products currently in development.
Reinforcing Cipla’s long-term vision, Vohra said, “Our ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability. We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion.”
Cipla reported a consolidated revenue of ₹27,548 crore in FY2024–25, with a consolidated net profit rising to ₹5,272 crore for the same period.